


Autophagy/virophagy: a “disposal strategy” to combat COVID-19

Dalibor Mijaljica^a and Daniel J. Klionsky ^b

^aIndependent Scholar; ^bDepartment of Molecular, Cellular, and Developmental Biology, and the Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA

ABSTRACT

Given the devastating consequences of the current COVID-19 pandemic and its impact on all of us, the question arises as to whether manipulating the cellular degradation (recycling, waste disposal) mechanism known as macroautophagy/autophagy (in particular, the selective degradation of virus particles, termed virophagy) might be a beneficial approach to fight the novel coronavirus, SARS-CoV-2. Knowing that “autophagy can reprocess everything”, it seems almost inevitable that, sooner rather than later, a further hypothesis-driven work will detail the role of virophagy as a fundamental “disposal strategy” against COVID-19, yielding most needed therapeutic interventions.

Abbreviations: ATG, autophagy-related; CoV/CoVs coronavirus/coronaviruses; COVID-19, coronavirus disease 2019; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

ARTICLE HISTORY

Received 9 June 2020
Revised 9 June 2020
Accepted 10 June 2020

KEYWORDS

Autophagy; coronavirus; disposal; virophagy; virus

The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the planet has emerged rapidly and unexpectedly as a global public health emergency by causing coronavirus disease 2019 (COVID-19), unprecedented chaos and panic, and a myriad of events affecting healthcare and socioeconomic well-being [1]. While instantaneous prevention, drastic social distancing and isolation measures implemented by worldwide governments and health organizations in control of the rapid spread of SARS-CoV-2 virus are absolutely essential, scientists around the world have quickly engaged in the challenging race against time by studying the basic cellular and molecular mechanisms/processes that can be used to fend off pathogenic coronaviruses (CoVs) (namely, SARS-CoV and its relatives, Middle East respiratory syndrome coronavirus [MERS-CoV] and the novel SARS-CoV-2) in humans as well as searching for effective therapeutic strategies against this deadly virus. Autophagy is one of these basic/fundamental and evolutionarily conserved cellular processes that “touches” every corner of the cell in terms of metabolism, regulation, membrane dynamics and, most prominently, intracellular degradation (also known as cellular recycling or waste disposal) [1–6].

Autophagy, in all its various forms, is responsible for (non) selective degradation of a divergent cellular cargo of unwanted, superfluous, harmful and defective cellular components (e.g., long-lived proteins, lipids, protein aggregates) enabling cells to quickly and efficiently generate recycled basic building materials/constituents (e.g., amino acids, fatty acids) and secure a sufficient energy supply in the face of a wide range of nutritional deficiencies, physiological conditions and pathophysiological cues, in order to increase fitness

at a cellular level and consequently at the organismal level. Additionally, as a multi-step and well-orchestrated (i.e., regulated by over 40 autophagy-related [ATG] proteins and numerous auxiliary/accessory proteins) process for maintaining homeostasis in the complex landscape of the eukaryotic cell, autophagy is the only pathway that is capable of degrading entire cellular organelles (e.g., mitochondria, peroxisomes, endoplasmic reticulum, the nucleus) and invading pathogens, including fungi, parasites, bacteria and viruses either randomly or in a targeted/selected fashion. Selective autophagy captures its cargo via the recruitment of selective autophagy receptors, including those involved in the autophagic degradation of viruses and viral-derived antigens via a specialized form of selective autophagy known as xenophagy (also termed virophagy, when referring to viruses) [7–11].

In the case of human viral infections, the induction of virophagy can be either proviral or antiviral. On the one hand, with regard to proviral virophagy, invading viruses have evolved strategies to escape, hijack, subvert, manipulate or even inhibit virophagic machinery, giving them replicative benefits. At present, various scientific (sometimes controversial) reports have converged on two important questions: whether CoVs induce virophagy, and whether the virophagy machinery and/or ATG proteins are involved in the infection and replication of CoVs. There is scientific evidence (with some discrepancies probably due to different viruses used, different cells tested and even the different techniques used in the study of virophagy/autophagy) indicating that virophagy plays an important role in viral replication and pathogenesis with CoVs, poliovirus, hepatitis C virus and dengue virus, which are all known to stimulate and require virophagy for accelerated replication. Therefore, inducing

autophagy could have adverse consequences for the overall disposal of these viruses, and there would be clear limits to the potential of autophagy/virophagy induction to fight viral infections. However, several subsequent studies have challenged the notion that virophagy is implicated in CoV infection. Thus, these observations suggest that the virophagy machinery is not directly implicated in the viral replication process, and it appears that there is a certain type of interplay between the virophagy machinery and CoVs, with the exact nature of such interactions to be further elucidated [1–6,10,12–15].

On the other hand, antiviral virophagy can: (1) selectively target viruses for degradation, (2) promote virus recognition and inflammatory cytokine responses, (3) regulate inflammation, (4) control cell survival, (5) promote antigen presentation and/or (6) be regulated in a paracrine-mediated fashion, a departure from the classic cell autonomous route. Intriguingly, a body of evidence indicates that CoVs may actually inhibit autophagy, which in turn suggests an antiviral role for autophagy. Accordingly, a number of studies have shown that increasing autophagic capacity may be beneficial against CoVs infection. Additionally, some specific accessory proteins, which by definition are not essential for CoVs replication but are involved in the modulation of host cells and immune evasion, may represent targets for reducing the autophagy-inhibitory effects of CoVs. While data regarding such attempts remain preliminary at this stage, we can speculate that autophagy/virophagy might be a possible druggable target for therapeutic interventions [1–6,10,12–15].

In the past two decades, the implication of virophagy in CoVs infection has attracted substantial attention, probably due to the following: (1) the SARS outbreak in 2002–2003, (2) the MERS-CoV outbreak in 2012, (3) the SARS-CoV-2 outbreak in 2019 and (4) the emerging field of autophagy research during the same period. The existing and newly-generated scientific evidence and publications allow for speculation that autophagy/virophagy induction might counteract CoV infection at different levels, although more specific data are certainly required. Irrespective of whether autophagy/virophagy modulation will eventually be part of the “disposal strategies” in the fight against COVID-19, it is essential to further establish and secure global healthcare as well as to promote and extend robust research including the potential role of autophagy/virophagy as it pertains to infectious diseases, including CoVs [1–15]. The biomedical research enterprise, scientists and researchers, including auto-phagy researchers, are more than willing to respond to the challenge of COVID-19; however, it has become apparent that much needed coordination among important constituencies is lacking. Therefore, it will certainly require a close academia-industry/biopharmaceuticals-government partnership in order to establish goals, set timetables, and form focused groups to deal with specific COVID-19 issues and make rapid progress in a collaborative framework for prioritizing therapeutic candidates and vaccines with predicted successful outcomes in order to minimize and even eliminate future CoVs/COVID-19-related hospitalizations and deaths.

Acknowledgments

The authors apologize to those whose work was not included here due to space limitations.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the National Institute of General Medical Sciences [GM131919].

ORCID

Daniel J. Klionsky  <http://orcid.org/0000-0002-7828-8118>

References

- [1] Carmona-Gutierrez D, Bauer MA, Zimmermann A, et al. Digesting the crisis: autophagy and coronaviruses. *Microb Cell*. 2020;7(5):119–128.
- [2] Ahmad L, Mostowy S, Sancho-Shimizu V. Autophagy-virus interplay: from cell biology to human disease. *Front Cell Dev Biol*. 2018;6:155.
- [3] Wong HH, Sanyal S. Manipulation of autophagy by (+) RNA viruses. *Semin Cell Dev Biol*. 2020;101:3–11.
- [4] Brest P, Benzaquen J, Klionsky DJ, et al. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war. Preprints. 2020. DOI:10.20944/preprints202004.0022.v1
- [5] Yang N, Shen H-M. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. *Int J Biol Sci*. 2020;16(10):1724–1731.
- [6] Gassen NC, Papies J, Bajaj T, et al. Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics. *bioRxiv Preprint*. 2020. DOI:10.1101/2020.04.15.997254
- [7] Yin Z, Pascual C, Klionsky DJ. Autophagy: machinery and regulation. *Microb Cell*. 2016;3(12):588–596.
- [8] Sharma V, Verma S, Seranova E, et al. Selective autophagy and xenophagy in infection and disease. *Front Cell Dev Biol*. 2018;6:147.
- [9] Yu L, Chen Y, Tooze S. Autophagy pathway: cellular and molecular mechanisms. *Autophagy*. 2018;14(2):207–215.
- [10] Dong X, Levine B. Autophagy and viruses: adversaries or allies? *J Innate Immun*. 2013;5:480–493.
- [11] Jacomin A-C, Gul L, Sudhakar P, et al. Nezis1 IP. What we learned from big data for autophagy research. *Front Cell Dev Biol*. 2018;6:92.
- [12] Khandia R, Dadar M, Munjal A, et al. A comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: current knowledge and prospects for disease prevention, novel drug design, and therapy. *Cells*. 2019;8(7):674.
- [13] Reggiori F, Monastyrska I, Verheije MH, et al. Coronaviruses hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. *Cell Host Microbe*. 2010;7(6):500–508.
- [14] Sumpter, Jr. R, Levine B. Selective autophagy and viruses. *Autophagy*. 2011;7(3):260–265.
- [15] Choi Y, Bowman JW, Jung JU. Autophagy during viral infection - a double-edged sword. *Nat Rev Microbiol*. 2018;16:341–354.